These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 27613525)

  • 1. A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts.
    Noro R; Ishigame T; Walsh N; Shiraishi K; Robles AI; Ryan BM; Schetter AJ; Bowman ED; Welsh JA; Seike M; Gemma A; Skaug V; Mollerup S; Haugen A; Yokota J; Kohno T; Harris CC
    J Thorac Oncol; 2017 Jan; 12(1):65-76. PubMed ID: 27613525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients.
    Der SD; Sykes J; Pintilie M; Zhu CQ; Strumpf D; Liu N; Jurisica I; Shepherd FA; Tsao MS
    J Thorac Oncol; 2014 Jan; 9(1):59-64. PubMed ID: 24305008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
    He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
    Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of microRNA expression in operable non-small cell lung cancer patients.
    Skrzypski M; Czapiewski P; Goryca K; Jassem E; Wyrwicz L; Pawłowski R; Rzyman W; Biernat W; Jassem J
    Br J Cancer; 2014 Feb; 110(4):991-1000. PubMed ID: 24448358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
    Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
    Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes.
    Skrzypski M; Dziadziuszko R; Jassem E; Szymanowska-Narloch A; Gulida G; Rzepko R; Biernat W; Taron M; Jelitto-Górska M; Marjański T; Rzyman W; Rosell R; Jassem J
    Clin Lung Cancer; 2013 Nov; 14(6):666-673.e2. PubMed ID: 23870818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer.
    Duncavage E; Goodgame B; Sezhiyan A; Govindan R; Pfeifer J
    J Thorac Oncol; 2010 Nov; 5(11):1755-63. PubMed ID: 20975375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung.
    Raponi M; Zhang Y; Yu J; Chen G; Lee G; Taylor JM; Macdonald J; Thomas D; Moskaluk C; Wang Y; Beer DG
    Cancer Res; 2006 Aug; 66(15):7466-72. PubMed ID: 16885343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
    Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
    Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p) coordinately targeted MTDH in lung squamous cell carcinoma.
    Mataki H; Seki N; Mizuno K; Nohata N; Kamikawaji K; Kumamoto T; Koshizuka K; Goto Y; Inoue H
    Oncotarget; 2016 Nov; 7(44):72084-72098. PubMed ID: 27765924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma.
    Wan YW; Beer DG; Guo NL
    Lung Cancer; 2012 Apr; 76(1):98-105. PubMed ID: 22047960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer.
    Sullivan I; Salazar J; Arqueros C; Andrés M; Sebio A; Majem M; Szafranska J; Martínez E; Páez D; López-Pousa A; Baiget M; Barnadas A
    Clin Transl Oncol; 2017 Jul; 19(7):884-890. PubMed ID: 28150169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signaling protein signature predicts clinical outcome of non-small-cell lung cancer.
    Jin BF; Yang F; Ying XM; Gong L; Hu SF; Zhao Q; Liao YD; Chen KZ; Li T; Tai YH; Cao Y; Li X; Huang Y; Zhan XY; Qin XH; Wu J; Chen S; Guo SS; Zhang YC; Chen J; Shen DH; Sun KK; Chen L; Li WH; Li AL; Wang N; Xia Q; Wang J; Zhou T
    BMC Cancer; 2018 Mar; 18(1):259. PubMed ID: 29510676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas.
    Yue D; Li H; Che J; Zhang Y; Tolani B; Mo M; Zhang H; Zheng Q; Yang Y; Cheng R; Jin JQ; Luh TW; Yang C; Tseng HH; Giroux-Leprieur E; Woodard GA; Hao X; Wang C; Jablons DM; He B
    PLoS One; 2015; 10(7):e0132134. PubMed ID: 26132438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of TPD52 by antitumor microRNA-218 suppresses cancer cell migration and invasion in lung squamous cell carcinoma.
    Kumamoto T; Seki N; Mataki H; Mizuno K; Kamikawaji K; Samukawa T; Koshizuka K; Goto Y; Inoue H
    Int J Oncol; 2016 Nov; 49(5):1870-1880. PubMed ID: 27633630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer.
    Tian L; Shan W; Zhang Y; Lv X; Li X; Wei C
    Pathol Oncol Res; 2016 Jan; 22(1):161-7. PubMed ID: 26453197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression profiling defines a recurrence signature in lung squamous cell carcinoma.
    Larsen JE; Pavey SJ; Passmore LH; Bowman R; Clarke BE; Hayward NK; Fong KM
    Carcinogenesis; 2007 Mar; 28(3):760-6. PubMed ID: 17082175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis.
    Tan X; Qin W; Zhang L; Hang J; Li B; Zhang C; Wan J; Zhou F; Shao K; Sun Y; Wu J; Zhang X; Qiu B; Li N; Shi S; Feng X; Zhao S; Wang Z; Zhao X; Chen Z; Mitchelson K; Cheng J; Guo Y; He J
    Clin Cancer Res; 2011 Nov; 17(21):6802-11. PubMed ID: 21890451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers.
    Robles AI; Arai E; Mathé EA; Okayama H; Schetter AJ; Brown D; Petersen D; Bowman ED; Noro R; Welsh JA; Edelman DC; Stevenson HS; Wang Y; Tsuchiya N; Kohno T; Skaug V; Mollerup S; Haugen A; Meltzer PS; Yokota J; Kanai Y; Harris CC
    J Thorac Oncol; 2015 Jul; 10(7):1037-48. PubMed ID: 26134223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer.
    Roepman P; Jassem J; Smit EF; Muley T; Niklinski J; van de Velde T; Witteveen AT; Rzyman W; Floore A; Burgers S; Giaccone G; Meister M; Dienemann H; Skrzypski M; Kozlowski M; Mooi WJ; van Zandwijk N
    Clin Cancer Res; 2009 Jan; 15(1):284-90. PubMed ID: 19118056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.